Management of prehypertension: Current status and future strategies

Current Hypertension Reviews

Volumn 7, Issue 2, 2011, Pages 118-124

  Sasamura, Hiroyuki ^a   Itoh, Hiroshi ^a   Julius, Stevo ^b  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

High normal blood pressure; Pharmacological therapy; Prehypertension; Prevention; Regression

Indexed keywords

CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; INDAPAMIDE; NIFEDIPINE; PLACEBO; RAMIPRIL; RESERPINE; TELMISARTAN;

ARTICLE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG MEGADOSE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PREHYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 80053462975     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340211797457854     Document Type: Article

References (81)

1. Robinson SC, Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med 1939; 64: 409-444.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
4. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
5. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
6. Ishikawa Y, Ishikawa J, Ishikawa S, et al. Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study. Hypertens Res 2008; 31: 1323-1330.
7. Elliott WJ, Black HR. Prehypertension. Nat Clin Pract Cardiovasc Med 2007; 4: 538-548.
8. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005; 11: CR403-CR409.
9. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-1010.
10. Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 1989; 84: 633-641.
11. Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 2007; 119: 237-246.
12. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. JAMA 1990; 264: 354-358.
13. Levy RL, Hillman CC, Stroud WD, White PD. Transient hypertension, its significance in terms of later development of sustained hypertension and cardiovascular-renal diseases. JAMA 1944; 126: 829-833.
14. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686.
15. Chiu YH, Wu SC, Tseng CD, Yen MF, Chen TH. Progression of pre-hypertension, stage 1 and 2 hypertension (JNC 7): a population-based study in Keelung, Taiwan (Keelung Communitybased Integrated Screening No. 9). J Hypertens 2006; 24: 821-828.
16. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991; 17: 22-27.
17. Winegarden CR. From prehypertension to hypertension? Additional evidence. Ann Epidemiol 2005; 15: 720-725.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
19. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
20. Liszka HA, Mainous AG, 3rd, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294-299.
21. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119: 133-141.
22. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006; 47: 410-414.
23. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007; 115: 855-860.
24. Ishikawa Y, Ishikawa J, Ishikawa S, et al. Prehypertension and the risk for cardiovascular disease in the Japanese general population: the Jichi Medical School Cohort Study. J Hypertens 2010; 28: 1630-1637.
25. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615.
26. Onat A, Yazici M, Can G, Kaya Z, Bulur S, Hergenc G. Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. Am J Hypertens 2008; 21: 890-895.
27. Izzo JL, Jr. Prehypertension: demographics, pathophysiology, and treatment. Curr Hypertens Rep 2007; 9: 264-268.
28. Egan BM, Nesbitt SD, Julius S. Prehypertension: should we be treating with pharmacologic therapy? Ther Adv Cardiovasc Dis 2008; 2: 305-314.
29. Kaplan NM. Treating prehypertension: a review of the evidence. Curr Hypertens Rep 2008; 10: 326-329.
30. Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol; 6: 21-30.
31. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539-543.
32. Egan BM, Julius S. Prehypertension: risk stratification and management considerations. Curr Hypertens Rep 2008; 10: 359-366.
33. Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep 1836; 1: 338-379.
34. Johnson GI. On certain points in the pathology of Bright's disease of the kidney. II. On the influence of the minute blood vessels upon the circulation. Tr Medico-Chir Soc Lond 1868; 51: 5575-76.
35. Ewald CA. Ueber die Veraenderungen kleiner Gefaesse bei Morbus Brightii und die darauf bezueglichen Theorien. Virchows Arch 1877; 71: 453-499.
36. Feihl F, Liaudet L, Levy BI, Waeber B. Hypertension and microvascular remodelling. Cardiovasc Res 2008; 78: 274-285.
37. Folkow B. Structural factor in primary and secondary hypertension. Hypertension 1990; 16: 89-101.
38. Lever AF, Harrap SB. Essential hypertension: a disorder of growth with origins in childhood? J Hypertens 1992; 10: 101-120.
39. Skov K, Mulvany MJ. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand 2004; 181: 397-405.
40. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
41. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: a disease of the microcirculation? Hypertension 2006; 48: 1012-1017.
42. Dilley JR, Stier CT, Jr. Arendshorst WJ. Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol 1984; 246: F12-F20.
43. Kimura K, Nanba S, Tojo A, Hirata Y, Matsuoka H, Sugimoto T. Variations in arterioles in spontaneously hypertensive rats. Morphometric analysis of afferent and efferent arterioles. Virchows Arch A Pathol Anat Histopathol 1989; 415: 565-569.
44. Gattone VH, 2nd, Evan AP, Willis LR, Luft FC. Renal afferent arteriole in the spontaneously hypertensive rat. Hypertension 1983; 5: 8-16.
45. Kario K. Preceding linkage between a morning surge in blood pressure and small artery remodeling: an indicator of prehypertension? J Hypertens 2007; 25: 1573-1575.
46. Julius S, Conway J. Hemodynamic studies in patients with borderline blood pressure elevation. Circulation 1968; 38: 282-288.
47. Drukteinis JS, Roman MJ, Fabsitz RR, et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 2007; 115: 221-227.
48. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in prediabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 2007; 30: 2708-2715.
49. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar diameter and risk for hypertension. Ann Intern Med 2004; 140: 248-255.
50. Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ 2004; 329: 79.
51. Smith W, Wang JJ, Wong TY, et al. Retinal arteriolar narrowing is associated with 5-year incident severe hypertension: the Blue Mountains Eye Study. Hypertension 2004; 44: 442-447.
52. Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006; 47: 189-194.
53. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-1303.
54. Giannotti G, Doerries C, Mocharla PS, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension; 55: 1389-1397.
55. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44: 413-418.
56. Julius S. Transition from high cardiac output to elevated vascular resistance in hypertension. Am Heart J 1988; 116: 600-606.
57. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res 1975; 36: 199-207.
58. Schiffrin EL. Vascular smooth muscle growth and extracellular matrix deposition: is there a role for the sympathetic nervous system? J Hypertens 2002; 20: 179-181.
59. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens 2011; 20(1): 37-43.
60. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33: 386-393.
61. Davies AA, Smith GD, Ben-Shlomo Y, Litchfield P. Low birth weight is associated with higher adult total cholesterol concentration in men: findings from an occupational cohort of 25,843 employees. Circulation 2004; 110: 1258-1262.
62. Law CM, de Swiet M, Osmond C, et al. Initiation of hypertension in utero and its amplification throughout life. BMJ 1993; 306: 24-27.
63. Wang G, Wang A, Tong W, Liu Y, Zhang Y. Association of elevated inflammatory and endothelial biomarkers with prehypertension among Mongolians in China. Hypertens Res 2011; 34: 516-520.
64. Stamler R, Stamler J, Gosch FC, et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA 1989; 262: 1801-1807.
65. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. Arch Intern Med 1990; 150: 153-162.
66. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657-667.
67. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144: 485-495.
68. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16: 603-614.
69. Lee RM, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991; 17: 141-150.
70. Gillies LK, Lu M, Wang H, Lee RM. AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Hypertension 1997; 30: 1471-1478.
71. Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659-666.
72. Sasamura H, Hayashi K, Ishiguro K, Nakaya H, Saruta T, Itoh H. Prevention and regression of hypertension: role of renal microvascular protection. Hypertens Res 2009; 32: 658-664.
73. Nakaya H, Sasamura H, Mifune M, et al. Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 2002; 91: 710-718.
74. Ishiguro K, Sasamura H, Sakamaki Y, Itoh H, Saruta T. Developmental activity of the renin-angiotensin system during the critical period modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007; 30: 63-75.
75. Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H. Pulse treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension 2009; 53: 83-89.
76. Rehman A, Schiffrin EL. Vascular effects of antihypertensive drug therapy. Curr Hypertens Rep 2010; 12: 226-232.
77. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
78. Skov K, Eiskjaer H, Hansen HE, Madsen JK, Kvist S, Mulvany MJ. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007; 50: 89-95.
79. Luders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-1496.
80. Zhang Y. Lessons from additional trials (CHINOM, PHARAO, and STRONG HEART). The first international conference on prehypertension and cardiometabolic syndrome (abstract) 2011.
81. Sasamura H, Nakaya H, Julius S, et al. Short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design. Hypertens Res 2008; 31: 1851-1857.